<?xml version="1.0" encoding="UTF-8"?>
<p>Historically, vaccine development has been aÂ long, risky, and costly endeavor. Planning vaccination against EIDs is especially challenging: The potential market for vaccines against these diseases is limited, and testing such vaccines is difficult [
 <xref ref-type="bibr" rid="CR17">17</xref>]. Several bottlenecks have been identified in the development of vaccines against EIDs [
 <xref ref-type="bibr" rid="CR18">18</xref>].
</p>
